Our founders’ insights and achievements

Caixa Capital Risc is leading the largest operation in the biotech sector in Spain, with a €55 million financing round in Sanifit

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

NuMat Medtech secures a €530,000 round of investment

Minoryx Therapeutics raises €21.3M in Series B funding round

QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102